262 related articles for article (PubMed ID: 20812791)
1. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
[TBL] [Abstract][Full Text] [Related]
2. Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
Faries D; Ascher-Svanum H; Phillips G; Nyhuis AW; Sugihara T; Stauffer V; Kinon BJ
BMC Med Res Methodol; 2012 Sep; 12():142. PubMed ID: 22974273
[TBL] [Abstract][Full Text] [Related]
3. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; George Awad A; Keefe RS; Naber D
Psychiatry Res; 2012 Dec; 200(2-3):835-42. PubMed ID: 22841345
[TBL] [Abstract][Full Text] [Related]
4. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.
Chen J; Ascher-Svanum H; Nyhuis AW; Case MG; Phillips GA; Schuh KJ; Hoffmann VP
Patient Prefer Adherence; 2011; 5():547-54. PubMed ID: 22114469
[TBL] [Abstract][Full Text] [Related]
5. Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation.
Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Kaiser D; Stauffer V; Shorr JM; Kinon BJ
Psychiatry Res; 2011 Oct; 189(3):463-8. PubMed ID: 21684017
[TBL] [Abstract][Full Text] [Related]
6. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
Weiden PJ
J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
[TBL] [Abstract][Full Text] [Related]
7. Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.
Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; Awad AG; Keefe RS; Naber D
Patient Prefer Adherence; 2012; 6():521-32. PubMed ID: 22879738
[TBL] [Abstract][Full Text] [Related]
8. Self-reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first-episode schizophrenia.
Stürup AE; Hjorthøj C; Jensen HD; Melau M; Davy JW; Nordentoft M; Albert N
Early Interv Psychiatry; 2023 Oct; 17(10):974-983. PubMed ID: 36693651
[TBL] [Abstract][Full Text] [Related]
9. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
Moritz S; Hünsche A; Lincoln TM
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
[TBL] [Abstract][Full Text] [Related]
10. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
11. Should antipsychotic medications for schizophrenia be given for a lifetime? Replication of a naturalistic, long-term, follow-up study of antipsychotic treatment.
Glick ID; Zamora D; Kamis D; Davis JM
CNS Spectr; 2019 Oct; 24(5):557-563. PubMed ID: 30777584
[TBL] [Abstract][Full Text] [Related]
12. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
14. Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up Study.
Glick ID; Davis JM; Zamora D; Ballon J; Nuthi M
J Clin Psychopharmacol; 2017 Apr; 37(2):125-130. PubMed ID: 28195931
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
16. [Relationships between insight and medication adherence in subjects with psychosis].
Droulout T; Liraud F; Verdoux H
Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
[TBL] [Abstract][Full Text] [Related]
17. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
18. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E; Carlson JP; Bloch MH
J Clin Psychiatry; 2015 Nov; 76(11):1535-45. PubMed ID: 26581028
[TBL] [Abstract][Full Text] [Related]
19. Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: a naturalistic 18-month follow-up study.
Vita A; Barlati S; Deste G; Corsini P; De Peri L; Sacchetti E
Psychiatry Res; 2012 Dec; 200(2-3):96-101. PubMed ID: 22858250
[TBL] [Abstract][Full Text] [Related]
20. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
